OPENING LETTER

The early days of the HIV epidemic gave rise to two epidemics: one that was viral in nature and another composed of fear, loathing and blame. Three decades into the epidemic, it remains clear:

HIV AND AIDS DON'T DISCRIMINATE; PEOPLE DO.

Since AIDS first appeared, we've made considerable progress in reducing new HIV infections and AIDS-related deaths. But our lack of progress in combating the epidemic of stigma, discrimination and social exclusion undermines our efforts in addressing the diagnosis of HIV and the treatment and care of people living with the virus. The persistence of stigma in the context of HIV also causes immense human hardship and diminishes us as a global community.

When we consider stigma and discrimination, stigma is often treated as a secondary matter. Although there has been a lot of lip service from international agencies to address stigma, the resources to enable an effective response to stigma at scale and duly tailored to different contexts have not been adequate. For example, global agendas for HIV prevention and treatment routinely recognize stigma as a major barrier to success. But we have yet to make fighting stigma a central pillar of our efforts in terms of allocating due resources to build a robust evidence base to enable effective anti-stigma policies and programming.

Since the beginnings of the HIV epidemic, there has been a tendency to conflate stigma and discrimination. However, while the two are related, they are also distinct. Stigma is a social phenomenon that elevates certain groups over others and steadily devalues entire groups of people.

Stigma can appear in a number of ways. Most notably, external factors can generate and reinforce stigma. These factors include pre-existing prejudice based on gender, race, sexuality or economic position and unfounded fear of HIV. The impact of stigma can also be intensely personal and internalized: individuals may feel ashamed, dirty or afraid, withdrawing from social situations and isolating themselves from others.

Yet, looking back on the past three decades of the epidemic, hope remains: HIV also gave rise to resilience, spirit and determination. So how do we, the HIV community – people whose lives are touched by HIV professionally or personally, who are living with HIV, who are vulnerable to HIV or who know someone affected by HIV – move beyond rhetoric to action in getting to the heart of stigma?

Kevin Osborne,
Executive Director
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABOUT THE IAS</td>
<td>4</td>
</tr>
<tr>
<td>MEMBERSHIP</td>
<td>5</td>
</tr>
<tr>
<td>IAS EDUCATIONAL FUND</td>
<td>8</td>
</tr>
<tr>
<td>HIV PROGRAMMES AND ADVOCACY</td>
<td>11</td>
</tr>
<tr>
<td>22ND INTERNATIONAL AIDS CONFERENCE (AIDS 2018)</td>
<td>24</td>
</tr>
<tr>
<td>GOVERNANCE</td>
<td>26</td>
</tr>
<tr>
<td>SUPPORTERS</td>
<td>28</td>
</tr>
<tr>
<td>FINANCIAL REPORTS</td>
<td>28</td>
</tr>
<tr>
<td>JOIN US!</td>
<td>29</td>
</tr>
</tbody>
</table>
ABOUT THE IAS

MISSION

The mission of the International AIDS Society (IAS) is to lead collective action on every front of the global HIV response through its membership base, scientific authority and convening power.

HOW WE DO IT

Science. The IAS pursues and supports scientific advancements that positively alter the course of the HIV epidemic and promote greater understanding of these discoveries. The IAS pushes for the full spectrum of scientific achievement – from basic science to implementation research – and uses the visibility of its meetings to highlight dynamic, innovative work.

People. The IAS invests in professionalizing and promoting the HIV workforce – particularly the next generation of HIV professionals – to build the skills and resources that are needed to end the epidemic. As a membership body, the IAS understands and represents the interests of its members in all of its work, retaining a global perspective that is relevant at a local level.

Progress. The IAS uses its scientific authority to move science into policy and policy into tangible impact against the epidemic. The IAS advocates for sustained global leadership and increased investment while keeping the fight against stigma and discrimination at the heart of its work.

For more information, read the IAS 2016-2020 organizational strategy.
MEMBERSHIP

The IAS is the world’s largest association of HIV professionals with members from more than 170 countries. Together, we advocate and drive urgent action to reduce the global impact of HIV.

Between July 2018 and July 2019, the IAS membership base reached 12,356 individuals, working at all levels of the global HIV response. IAS Members include researchers, clinicians, service providers, policy makers, people living with HIV and community advocates.

IAS GENERAL MEMBERS’ MEETING

To build a strong, informed and connected IAS membership body, the IAS convenes the annual IAS General Members’ Meeting.

On 26 July 2018, the IAS General Members’ Meeting, including the David Cooper remembrance session, took place during the 22nd International AIDS Conference (AIDS 2018) in Amsterdam, the Netherlands. More than 400 IAS Members attended the meeting, chaired by IAS President Linda-Gail Bekker, and the David Cooper remembrance session, chaired by former IAS President Françoise Barré-Sinoussi and IAS Governing Council member Sharon Lewin.

In addition to the IAS General Members’ Meeting, regional members’ meetings took place at the conference.

CAPACITY BUILDING

HIV science evolves rapidly, requiring constant interpretation, translation and knowledge exchange. This year, the IAS committed itself to promoting greater understanding of HIV science and policy in order to build the skills and resources that are needed to end the epidemic – retaining a global perspective that is relevant at a local level.

As part of this commitment, the IAS published the third edition of the knowledge toolkits series, developed exclusively for IAS Members, highlighting important scientific advancements and innovative research presented at its conferences. The AIDS 2018 Knowledge Toolkits offer adaptable PowerPoint presentations with an easy navigation system and printable speaker notes covering the five scientific tracks presented at AIDS 2018.

This series will continue with IAS 2019 Knowledge Toolkits providing more research and tools for IAS Members. For open-access toolkits from AIDS 2016 and IAS 2017, visit the knowledge toolkits archive.

Learn how to access these toolkits and other exclusive IAS Member benefits here: https://www.iasociety.org/Membership/Become-a-Member/Benefits.
The #IASONEVOICE membership campaign continued for the fourth year, highlighting the key topics most important to IAS Members and sharing their personal perspectives from working and volunteering on all fronts of the HIV response. In February 2019, the IAS launched the #IASONEVOICE Instagram campaign, including the #IASONEVOICE on Women and Girls in Science series. This year, the campaign featured the following stories and opinions:
BY THE NUMBERS

The following graphics provide a breakdown of IAS membership from this calendar year.

MEMBERS BY REGION

MEMBERS BY PROFESSION

MEMBERS BY GENDER

TOP 10 MEMBER NATIONS

- United States
- South Africa
- France
- United Kingdom
- Netherlands
- Canada
- Kenya
- Uganda
- United Kingdom
- Nigeria
IAS EDUCATIONAL FUND

TRANSLATING THE SCIENCE AND CAPACITY BUILDING

The IAS Educational Fund aims to provide educational and training opportunities to frontline HIV professionals. In its third year, this essential programme of the IAS is continuing to receive growing support and has undergone exciting new developments.

Further to growing demand and through feedback received from HIV professionals during activities implemented by the programme since 2016 (scholarships, regional meetings and online resources), the IAS Educational Fund launched three new initiatives this year: scientific publishing workshops; a new press fellowship programme; and a series of webinars.

1. In Ghana and Zimbabwe, the IAS Educational Fund implemented scientific publishing workshops to support local scientists to improve their ability to compete successfully for acceptance of their abstracts at international conferences and publish their research findings in international peer-reviewed journals. Drawing on the expertise in academic publishing available through the Journal of the International AIDS Society (JIAS), these new in-country workshops were aimed at linking local and regional science back into global scientific debates.

2. In 2019, the IAS Educational Fund also launched a new press fellowship programme in Ghana and Zimbabwe with the aim of advancing on-the-ground media coverage of key HIV-related science, research and implementation. Journalists from local, regional and international media outlets were exposed to the latest HIV science and the way it is contextualized in each country to strengthen their ability to inform a broader public of the latest advances in prevention, treatment and care of HIV and co-infections. The IAS drew on its experience with media scholarships from AIDS conferences to implement this new initiative.

3. In addition, the IAS also made scientific content available to HIV professionals through new webinars. These online sessions of similar content to the in-person meetings provided space for continuous capacity building, including debriefing the latest scientific advances from AIDS 2018, and scientific publishing support in collaboration with JIAS. To follow up on in-country meetings that took place in Morocco and Thailand in 2017, the IAS hosted a series of online sessions; these also provided an avenue to exchange practical examples of having translated science into concrete activities on the ground, and continue to discuss achievements, challenges, possible solutions and further action.
The IAS Educational Fund continued to offer fellowship opportunities. It also continued to make dynamic, scientific fora accessible to HIV professionals by providing direct support to clinicians and other HIV service providers to attend our global conferences and by providing subtitles in several languages for the content of selected AIDS 2018 sessions.

In addition, the IAS Educational Fund increasingly worked to connect new international research and practice with local contexts with regional meetings targeted at healthcare workers, advocates and policy makers to provide access to the latest science and opportunities to question how that information impacts local epidemics.
REGIONAL MEETINGS

MONTREAL, CANADA
TITLE: Science and Community in the HIV Response in the Caribbean
DATE: 28-29 November 2018
PARTNER ORGANIZATION: Les Centres GHESKIO

Dakar, Senegal
TITLE: Science and Community in the HIV Response in Western Africa
DATE: 12-13 May 2019
PARTNER ORGANIZATION: Planned Parenthood Association of Ghana

Beirut, Lebanon
TITLE: Translating HIV Science into Practice in the MENA Region
DATE: 28-30 June 2019
PARTNER ORGANIZATION: American University of Beirut

Jakarta, Indonesia
TITLE: Test and Treat: Innovative Ways Forward
DATE: 8-9 December 2018
PARTNER ORGANIZATION: Indonesia AIDS Coalition

Bogota, Colombia
TITLE: Responses to HIV and Migration in Latin America: Current Challenges and Future Strategies
DATE: 3 April 2019
PARTNER ORGANIZATION: Viral Infections Latin America (VILA) and the Latin American HIV Workshop Study Group

Rio de Janeiro, Brazil
TITLE: Science and Community in the HIV Response in South America
DATE: 26-27 March 2019
PARTNER ORGANIZATION: National Emergency Response Council on HIV and AIDS

Tbilisi, Georgia
TITLE: Translating Science to End HIV in Eastern Europe and Central Asia
DATE: 20 June 2019
PARTNER ORGANIZATION: Center for Information and Counseling on Reproductive Health – PANADOMA

Harare, Zimbabwe
TITLE: Science, Community and Youth in the HIV Response in Southern Africa
DATE: 24 June 2019
PARTNER ORGANIZATION: Africaid Zvandiri

Buenos Aires, Argentina
TITLE: Science, Community and Youth in the HIV Response in Latin America
DATE: 31 March 2019
PARTNER ORGANIZATION: Viral Infections Latin America (VILA) and the Latin American HIV Workshop Study Group
HIV PROGRAMMES AND ADVOCACY

The IAS HIV Programmes and Advocacy department works to promote the implementation of evidence-informed and human rights-based strategies for improving the lives of people living with and most vulnerable to acquiring HIV.

Through its various programmes, the department harnesses research, shapes the evidence base and amplifies the voices of communities living with and affected by HIV to influence policy across and beyond the HIV prevention-to-care continuum. To do this, the department undertakes advocacy, supports capacity building and engages in collaborative partnerships with a range of organizations, including civil society and communities around the world.

The HIV Programmes and Advocacy operational strategy for 2017-2020 initiates action across three linked domains: policy, research and structural barriers.

**Policy:** Influence global and national HIV policy and bridge gaps between the HIV response and the broader integrated health landscape.

**Research:** Inspire HIV research targeting scientific gaps in strategic priority areas.

**Structural barriers:** Instigate action to remove structural barriers and address human rights violations that prohibit access to and uptake of comprehensive HIV services for selected populations and communities.

Across its broad platform of work, the IAS HIV Programmes and Advocacy department maintains a focus on three cross-cutting issues: human rights, gender and youth. Each of the department’s programmes is intended to purposely incorporate and mainstream these issues into its activities.
The expansion of prevention of mother-to-child transmission interventions has led to fewer infants being born with HIV but many children continue to go undiagnosed. Only 43% of all children living with HIV are accessing antiretroviral treatment and critical barriers to scaling up paediatric HIV treatment and care remain. Innovative testing, treatment and service delivery strategies are needed to simplify and expand paediatric services.

Guided by a world-class Scientific Technical and Advisory Committee of experts in paediatric and adolescent HIV, CIPHER works to promote and invest in targeted research to: address priority knowledge gaps in paediatric and adolescent HIV; convene stakeholders and establish collaborative mechanisms to strengthen communication, knowledge transfer and exchange of data and good practice between paediatric and adolescent HIV cohorts; and advocate to support evidence-informed clinical, policy and programmatic decision making for the paediatric and adolescent HIV response.

In 2018, CIPHER undertook a strategy review to ensure it remains effective in the changing landscape of paediatric and adolescent HIV, increased its focus on operational science and expanded CIPHER global cohort collaboration.

https://www.iasociety.org/CIPHER

FEATURED WORK (RESEARCH)

The CIPHER Global Cohort Collaboration reached a major milestone with the publication of its first papers. “The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis”, is the first global description of the epidemic in adolescents with perinatally acquired HIV.
DIFFERENTIATED SERVICE DELIVERY

Now, as ever, it is critical to acknowledge the diverse needs of people living with HIV. Differentiated service delivery (DSD) is a client-centred approach that simplifies and adapts HIV services across the cascade in ways that both serve the needs and expectations of people living with HIV and reduce unnecessary burdens on the health system. The IAS Differentiated Service Delivery initiative is committed to supporting the scale up of DSD through catalysing country and community advocacy and amplifying global best practices, tools and evidence to effectively reach the 37 million people worldwide in need of high-quality life-saving HIV care.

In 2018, the DSD initiative expanded its focus to HIV testing services and DSD for key populations, while continuing to work in the area of differentiated antiretroviral therapy delivery. In addition, the initiative supported uptake and adoption of national DSD policies and guidelines as well as community-driven demand creation for DSD.

https://www.iasociety.org/Differentiated-Service-Delivery

FEATURED WORK (POLICY)

The DSD initiative supported national policy uptake of differentiated antiretroviral treatment delivery in Ethiopia, Ghana and Sierra Leone. At a global policy level, the work of the initiative is referenced in technical guidance from the World Health Organization, the United States President’s Emergency Plan for AIDS Relief and the Global Fund to Fight HIV, Tuberculosis and Malaria.
HIV CO-INFECTIONS AND CO-MORBIDITIES

Among people living with HIV, morbidity and mortality is increasingly driven by co-infection with other diseases, including hepatitis C and tuberculosis, and co-morbidity with non-communicable diseases. Successfully addressing the challenge of co-infections and co-morbidities requires tackling the complexities of multiple public health concerns, including reaching vulnerable populations and expanding access to new diagnostics and curative medicines.

The IAS HIV Co-Infections and Co-Morbidities initiative focuses on several areas, notably paying particular attention to communities most affected by and service delivery needs related to HIV, such as tuberculosis, hepatitis, mental health and other non-communicable diseases or integration of sexual and reproductive services for people living with HIV.

Activities in 2018 focused on increasing the awareness of structural barriers that compromise the health and human rights of people who inject drugs and links between HIV and viral hepatitis. The work has also expanded to other co-infections and co-morbidities, such as TB, where the initiative has focused on fostering partnerships for future activities.

https://www.iasociety.org/Co-Infections/Hepatitis

FEATURED WORK (STRUCTURAL BARRIERS)

Released on World Hepatitis Day 2018, the policy brief, “Ending an epidemic: Prioritizing people who inject drugs in HCV elimination efforts”, advocates for scaling up needle and syringe programmes and opioid substitution therapy alongside treatment for hepatitis C.
Critical gaps remain across the HIV care continuum, from research and development to manufacturing, delivery and uptake of medical innovations to the people who most need them. In this context, the ILF works to promote and facilitate the full contribution of the biomedical industry to the global HIV response, bringing to the foreground the contribution of an interdisciplinary group on current and emerging issues in global health. In particular, the ILF builds on its collaborative platform to address challenges in paediatric HIV (to fast track the development of paediatric HIV medicines) and regulatory affairs (to support more efficient regulatory processes).

ILF activities in 2018 focused on supporting rapid access to new technologies and treatment and prevention options. These included streamlining WHO Prequalification processes for in vitro diagnostics, regulatory pathways and clinical trial design for long-acting pre-exposure prophylaxis (PrEP) as well as supporting the development of the Global Accelerator for Paediatric Formulations (GAP-f).

https://www.iasociety.org/ILF

FEATURED WORK (POLICY)

ILF published a viewpoint, “The Manufacturers’ Perspective on WHO Prequalification of In Vitro Diagnostic” and released an ILF policy brief on advance procurement of prioritized paediatric drug formulations.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (JIAS)

JIAS is a peer-reviewed and PubMed- and Medline-indexed journal that publishes the latest HIV research online and free of charge to readers. As a multidisciplinary journal, it generates and disseminates quality academic publications on a variety of topics, ranging from social, behavioural, political and economic research to biomedical and clinical research, while leading the way in implementation and operational research.

In addition to publishing special thematic supplements, JIAS invests in strengthening the capacity and confidence of early-career researchers from low- and middle-income countries and in creating platforms for dissemination of their research.

In 2018, the journal published special issues on key topics such as “Paediatric and Adolescent HIV and the Sustainable Development Goals: the road ahead to 2030”, “Towards global viral hepatitis elimination for all patients in all income settings”, “Population mobility: challenges for universal HIV testing and treatment”, “Optimizing the impact of key population programming across the HIV cascade” and “Science, theory, and practice of engaged research: Good Participatory Practice and beyond”. JIAS received its first impact factor of 3.256 in 2012 and this rose to 5.135 in 2018. JIAS ranked 10th out of 88 “Infectious Diseases” journals and 37th out of 155 “Immunology” journals.

www.jiasociety.org

FEATURED WORK (RESEARCH)

The journal published the special issue, “Science, theory, and practice of engaged research: Good Participatory Practice and beyond”, to report on experiences of effectively incorporating community and stakeholder perspectives into HIV clinical trials.
NOBODY LEFT BEHIND
KEY POPULATIONS COUNT

The substantial gains made in the global HIV response in recent years have not been shared equally across all groups. Key populations – men who have sex with men, people who inject drugs, sex workers and transgender people – are at increased vulnerability of acquiring HIV. Stigma, discrimination and violence increase the vulnerability of key populations to ill-health and create obstacles for accessing quality and comprehensive health and other services.

The Nobody Left Behind initiative gives prominence to the challenges faced by key populations and works towards removing barriers affecting their access to HIV prevention, treatment and care services.

In 2019, the Annual Letter sent to IAS Members in February launched a new campaign to get to the #HeartOfStigma. A series of campaign activities and partnership engagement has followed, building a strong foundation for the growth of the campaign throughout the year.

www.iasociety.org/nobody-left-behind

FEATURED WORK (POLICY)

At AIDS 2018, the Nobody Left Behind initiative hosted an invite-only meeting on the topic, “Do no harm – Safety and security in the implementation of key population programmes”. This informal “catalyst conversation” brought together 45 policy, community representatives, funders, advocates and healthcare providers to discuss why safety and security is such an issue for programmes tailored to key populations and solutions to strengthen our response to security and safety concerns.
The toolbox of interventions in the HIV response has dramatically expanded since the discovery of the virus. A cure has remained beyond our grasp but research to develop a cure for HIV or long-term remission has made promising progress, spurring renewed excitement in the field among researchers, advocates and community members alike.

The mission of the Towards an HIV Cure initiative is to drive concerted efforts to accelerate global scientific research and engagement towards a cure for HIV.

Activities in 2018 focused on advancing the HIV cure field in resource-constrained settings through capacity-building and training workshops for researchers and advocates, informing and empowering a multi-disciplinary network of stakeholders to advocate for the prioritization of an HIV cure in the global health agenda.

https://www.iasociety.org/hivcure

The initiative is promoting the next generation of HIV cure researchers in resource-limited settings by awarding fellowships to talented early to mid-career investigators who are conducting HIV research in resource-limited settings to participate in the annual Research-for-Cure Academies and related mentorship programme.
ADOLESCENT HIV TREATMENT COALITION (ATC)

Hosted by the IAS, the ATC is made up of a diverse group of stakeholders in the HIV response united to advocate for quality treatment and care for all adolescents living with HIV. The ATC is governed by a steering committee of organizations that are led by and serve young people. It provides a collective voice promoting accountability in the HIV response to the realities of adolescent lives. As part of its advocacy portfolio, it calls attention to gaps, proposes solutions and works collaboratively on a range of adolescent treatment issues.

Activities in 2018 focused on supporting a more coordinated and sustainable response by young people to the epidemic, strengthening the position of the ATC as a leading advocacy voice and responding to the increasing amount of requests the ATC receives to represent the voice of young people living with HIV through improved coordination and governance.

https://www.iasociety.org/Adolescent-HIV-Treatment-Coalition

FEATURED WORK (STRUCTURAL BARRIERS)

In the first six months of 2018, the ATC doubled its membership, including nine new organizations, added a regional network of young people living with HIV to its steering committee and supported the PACT and the Amsterdam Youth Force in their preparations for AIDS 2018.
GLOBAL HIV VACCINE ENTERPRISE

The HIV vaccine field has built considerable momentum in recent times with multiple efficacy-stage programmes underway and new vaccine concepts in the clinical pipeline. The range of opportunities and possibilities is matched by an understanding and sense of urgency that the field is underprepared for complex challenges that remain. Under its newly launched strategic plan (2018-2023), the Global HIV Vaccine Enterprise (known as the Enterprise) works in close collaboration with major HIV vaccine stakeholders towards ensuring that the field is sustained by a robust portfolio of vaccine candidates in clinical trials, is prepared for making a successful vaccine available to all and is propelled by increased and diversified funding for research and development.

In 2018, building on its convening power, the IAS brought together a range of stakeholders to support a strategic review of the work, aims and objectives of the Enterprise. These meetings led to the launch of the Enterprise Strategic Plan 2018-2023 which emphasizes the importance of fostering a collaborative research and development environment, preparing for imminent efficacy trial outcomes and the continuing need to advocate for adequate financial resources in the context of fast-changing HIV prevention and treatment.

https://www.iasociety.org/Global-HIV-Vaccine-Enterprise

FEATURED WORK (POLICY)

Launched in October 2018, the renewed five-year strategy aims to advance a shared vision to develop a safe and effective HIV vaccine available to the world.
OUR CAMPAIGNS

ME AND MY HEALTHCARE PROVIDER

The Me and My Healthcare Provider campaign, part of the Nobody Left Behind initiative, puts a spotlight on the frontline healthcare providers who address the HIV-related needs of key populations, often in the face of discriminatory laws, traditions and belief systems. Based on the personal experiences and stories shared by Healthcare Provider Champions, the campaign fosters a better understanding of the factors that enable healthcare practitioners to be #DoingTheRightThing.

In 2018, four healthcare providers (from Kazakhstan, Lebanon, Malawi and Uganda) were recognized at the special session of AIDS 2018 by artist Conchita Wurst and The Honourable Edwin Cameron, Justice of the Constitutional Court of South Africa. Their stories were published in the Quarterly Member’s email on 1 March 2019, Zero Discrimination Day, to urge other frontline healthcare providers to follow their best practice examples. Their stories are available here.

https://www.iasociety.org/Me-and-My-Healthcare-Provider
YOUTH VOICES

Youth Voices is an advocacy campaign that supports the active participation of adolescents in the HIV response through educational opportunities, financial support, tailored resources and amplifying personal stories to help shape key policy decisions.

The campaign focuses on expanding leadership by young people across a range of community-based organizations through a Youth Champion seed grant programme on key priority topics, shaping collective advocacy through films and policy briefs to highlight young people’s contributions to and needs in the HIV response, and strengthening capacity and providing networking opportunities to young people at international meetings and conferences.

Last year, 30 young people (aged 18-26 years) from 21 countries took part in the AIDS 2018 Youth Ambassador Programme. The Youth Ambassadors benefitted from a four-day curriculum. It included opportunities such as: meetings with leading scientists, researchers and advocates; abstract writing and resource mobilization training; one-on-one career forums to discuss individual career pathways in the field of HIV; and networking with other young people living with HIV, young activists and young researchers. More information and materials are available here.

https://www.iasociety.org/Youth-Voices
GENERATION NOW

Generation Now: Our Health, Our Rights is a bold partnership between the IAS and Women Deliver that contributes to achieving health and rights, particularly for adolescent girls and young women, by increasing political and financial investment across sectors in support of integrated HIV and sexual and reproductive health and rights (SRHR) responses. Ensuring universal access to SRHR services, achieving gender equality and empowering young people, including adolescent girls and young women and their partners to exercise their SRHR, are critical for an effective HIV response. Yet HIV and SRHR responses are still often placed in silos.

The Generation Now partnership awarded 10 grants to selected advocacy organizations through the Generation Now Core Group youth members to develop grassroots projects globally with the aim of building on the latest global discussions on integrating young people-friendly SRHR and HIV health services and ensuring access to education and information for adolescent girls and young women.

https://www.iasociety.org/HIV-Programmes/Campaigns/Generation-Now
**22ND INTERNATIONAL AIDS CONFERENCE (AIDS 2018)**

“Together, we hold policy makers and donors accountable to the evidence. The end of AIDS will only come from prioritizing science-based policies, ensuring adequate funding and working together ensure no one is left behind.” - Linda-Gail Bekker, President of the IAS and International Chair of AIDS 2018

In July 2018, more than 14,000 delegates from over 175 countries gathered at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam for the largest conference on HIV in the world, under the theme *Breaking Barriers, Building Bridges*. Nearly 3,000 abstracts from more than 100 countries presented breaking science, research and insights across the spectrum of HIV sciences.

Highlights from the conference included: presentations on rights-based approaches in Eastern Europe to more effectively reach key populations; promising results of potential new vaccines; innovations in diagnostic technologies; and preliminary findings from the rollout of PrEP in key countries. By the end of the conference, thousands of delegates had signed the Amsterdam Affirmation, confirming their commitment to supporting sustainability, ending exclusion and amplifying the voices of advocates.

<table>
<thead>
<tr>
<th>14,000 PARTICIPANTS</th>
<th>FROM OVER 175 COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,267 SCHOLARSHIP RECIPIENTS</td>
<td>775 MEDIA REPRESENTATIVES</td>
</tr>
<tr>
<td>39 MEDIA SCHOLARSHIP RECIPIENTS</td>
<td></td>
</tr>
</tbody>
</table>
BY THE HEADLINES

“Dangerous complacency’ looms over world AIDS meeting” from AFP

“Sida: La PrEP, Ça Marche!” in Libération

“Zero Transmissions Mean Zero Risk – PARTNER 2 Study Results Announced” in AIDSmap.com

“Troubling Questions Remain About Whether A Popular HIV Drug Causes Birth Defects” in Science

“Prince Harry, Elton John Honor Princess Diana’s Legacy With AIDS Conference” on FOX News

“How Trump’s Abortion Gag Rule Policy Impacts The Global AIDS Crisis” on CNN

BY THE NUMBERS

184k MINUTES OF FREELY AVAILABLE CONFERENCE VIDEO

3.3M PEOPLE REACHED THROUGH OFFICIAL AIDS 2018 SOCIAL MEDIA CHANNELS

1.17B TOTAL MEDIA IMPRESSIONS
GOVERNANCE

IAS GOVERNING COUNCIL
The Governing Council is the executive body of the IAS. It approves the annual budget and presents financial and other information to the General Members’ Meeting at each International AIDS Conference and each IAS Conference on HIV Science. Furthermore, the Governing Council is responsible for all the functions that are not attributed to another organ of the IAS.

From left to right:

President Anton Pozniak,

President-Elect Adeeba Kamarulzaman,

Treasurer Celia DC Christie-Samuels,

Immediate Past President Linda-Gail Bekker,

Executive Director Kevin Osborne.
IAS EXECUTIVE COMMITTEE

The IAS Executive Committee acts on behalf of the IAS Governing Council and provides effective oversight and review of the IAS’s operations and finances between Governing Council meetings. The committee also reviews and appraises the performance of the IAS Executive Director.

The Executive Committee consists of the President, President-Elect, Treasurer and one Regional Representative selected from the Governing Council members of each region, as well as the Executive Director as a non-voting member. The President may also invite other Governing Council members to Executive Committee meetings to participate in discussions of matters within their area of expertise.

AFRICA
Kenneth Ngure*
Serge Paul Ehliqué
James G Hakim
Keletso Makofane

ASIA AND THE PACIFIC ISLANDS
Sharon Lewin*
Ishwar Gilada
Shuzo Matsushita
Nittaya Phanuphak

EUROPE
Jürgen Rockstroh*
Andriy Klepikov
Cristina Mussini
Bruno Spire

LATIN AMERICA AND THE CARIBBEAN
Horacio Salomon*
Beatriz Grinsztejn
Russell Pierre
Luis Soto-Ramirez

UNITED STATES AND CANADA
Marina Klein*
Adaora Adimora
Judith Auerbach
Jennifer Kates

* Regional representative on the IAS Executive Committee
SUPPORTERS

THANK YOU TO OUR SUPPORTERS WHO FUNDED ACTIVITIES FROM JULY 2018 TO JUNE 2019

We would like to thank our dedicated supporters, without whom we could not realize the impact of our work.

Abbott Molecular
AbbVie
Abivax
AFEW International
Agence de recherche ANRS (France Recherche Nord & Sud Sida - HIV Hépatites)
Amsterdam Public Health Service
Aurobindo
Beckman Coulter
Bill & Melinda Gates Foundation
Canada – Global Affairs Canada
Canada – Public Health Agency of Canada
Cepheid
Chevron Corporation
Cipla
City of Amsterdam
Conrad N. Hilton Foundation
Coral Healthcare
Elton John AIDS Foundation
Ford Foundation
Gilead Sciences
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Government of Flanders
Hetero Labs
Imperial Logistics
Janssen Pharmaceutical
Johnson & Johnson
Joint United Nations Programme on HIV/AIDS (UNAIDS)
Lupin Pharmaceuticals
Luxembourg, Ministry of Foreign and European Affairs
MAC AIDS Fund
Merck Sharp & Dohme
Mylan
National Postcode Lottery of the Netherlands
The Netherlands – Ministry of Foreign Affairs
The Netherlands – Ministry of Health, Welfare and Sport
The Netherlands National Institute for Public Health and the Environment
Omega Diagnostics
OPEC Fund for International Development
Open Society Foundations
Paediatric AIDS Treatment for Africa
PENTA Foundation
Roche
Sidaction
Simons Foundation
Stop TB Partnership
Sysmex
Swiss Agency for Development and Cooperation (SDC)
United Nations Children’s Fund (UNICEF)
United Nations Development Programme (UNDP)
USAID
U.S. National Cancer Institute
U.S. National Institute of Allergy and Infectious Diseases
U.S. National Institutes of Health – Office of the Director
U.S. National Institute on Aging
U.S. National Institute on Drug Abuse
ViV Healthcare
World Health Organization (WHO)

FINANCIAL REPORTS

JOIN US!

BECOME AN IAS MEMBER
Join the collective voice of policy makers, researchers, scientists and community members to shape the global HIV response. Visit https://www.iasociety.org/membership to learn more about our work and the benefits of becoming a member.

STAY UP TO DATE
Join the IAS mailing list by visiting https://www.iasociety.org/Mailing-list-sign-up to receive the latest news, updates and announcements.

SPREAD THE WORD AND JOIN THE CONVERSATION

www.facebook.com/iasociety
www.twitter.com/iasociety
@iasociety
www.linkedin.com/iasociety
www.youtube.com/iasociety